Schedule 13G ownership disclosure
Menlo Therapeutics, Inc.
Security class unavailable · CUSIP: 586858102
Event date: 2018-01-25
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 4,011,236
- Percent of class
- 17.5000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001615774-18-000813
- Form type
- SC 13G
- Filer
- VYNE Therapeutics Inc.
- CIK
- CIK 1566044
- Filed
- Feb 02, 2018
- Reporting period
- Jan 25, 2018
- Description
- Schedule 13G beneficial ownership